PMID- 26366084
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150914
LR  - 20201001
IS  - 1176-6328 (Print)
IS  - 1178-2021 (Electronic)
IS  - 1176-6328 (Linking)
VI  - 11
DP  - 2015
TI  - Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a 
      systematic review and meta-analysis of randomized controlled trials.
PG  - 2299-307
LID - 10.2147/NDT.S91397 [doi]
AB  - OBJECTIVE: We conducted a systematic review and meta-analysis of the efficacy of 
      aripiprazole once monthly (AOM) for schizophrenia. METHODS: Randomized controlled 
      trials (RCTs) on AOM, published until June 25, 2015, were retrieved from PubMed, 
      Cochrane, and PsycINFO databases. Relative risk (RR), standardized mean 
      difference (SMD), 95% confidence intervals (95% CIs), and numbers needed to 
      treat/harm (NNT/NNH) were calculated. RESULTS: We identified four relevant RCTs 
      (total n=1,860), two placebo-controlled trials, one noninferiority trial 
      comparing AOM to oral aripiprazole (OA), and one including therapeutic doses of 
      AOM and OA, as well as an AOM dose below therapeutic threshold (control arm). AOM 
      was superior to placebo for decreasing Positive and Negative Syndrome Scale 
      (PANSS) total scores (SMD =-0.65, 95% CI =-0.90 to -0.41, n=1,126). However, 
      PANSS total scores did not differ significantly between pooled AOM and OA groups. 
      The pooled AOM group showed significantly lower incidence of all-cause 
      discontinuation (RR =0.54, 95% CI =0.41-0.71, n=1,139, NNH =4) and inefficacy (RR 
      =0.28, 95% CI =0.21-0.38, n=1,139, NNH =5) than placebo, but was not superior to 
      placebo regarding discontinuation due to adverse events (AEs) or death. The AOM 
      group exhibited a lower incidence of all-cause discontinuation than OA (RR =0.78, 
      95% CI =0.64-0.95, n=986, NNH =14), but there were no intergroup differences in 
      discontinuation due to inefficacy, AEs, or death. There were no significant 
      differences in extrapyramidal symptoms scale scores between AOM and placebo or 
      between AOM and OA. AOM resulted in higher weight gain than placebo (SMD =0.41, 
      95% CI =0.18-0.64, n=734) but lower than OA (SMD =-0.16, 95% CI =-0.29 to -0.02, 
      n=847). CONCLUSION: AOM has antipsychotic efficacy and low risk of 
      discontinuation due to AEs.
FAU - Oya, Kazuto
AU  - Oya K
AD  - Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, 
      Aichi, Japan.
FAU - Kishi, Taro
AU  - Kishi T
AD  - Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, 
      Aichi, Japan.
FAU - Iwata, Nakao
AU  - Iwata N
AD  - Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, 
      Aichi, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150903
PL  - New Zealand
TA  - Neuropsychiatr Dis Treat
JT  - Neuropsychiatric disease and treatment
JID - 101240304
PMC - PMC4562720
OTO - NOTNLM
OT  - aripiprazole once monthly
OT  - efficacy
OT  - meta-analysis
OT  - safety
OT  - schizophrenia
OT  - systematic review
EDAT- 2015/09/15 06:00
MHDA- 2015/09/15 06:01
PMCR- 2015/09/03
CRDT- 2015/09/15 06:00
PHST- 2015/09/15 06:00 [entrez]
PHST- 2015/09/15 06:00 [pubmed]
PHST- 2015/09/15 06:01 [medline]
PHST- 2015/09/03 00:00 [pmc-release]
AID - ndt-11-2299 [pii]
AID - 10.2147/NDT.S91397 [doi]
PST - epublish
SO  - Neuropsychiatr Dis Treat. 2015 Sep 3;11:2299-307. doi: 10.2147/NDT.S91397. 
      eCollection 2015.